78 related articles for article (PubMed ID: 1818150)
1. Hemolytic properties of lytic peptides active against the sporozoites of Cryptosporidium parvum.
Arrowood MJ; Jaynes JM; Healey MC
J Protozool; 1991; 38(6):161S-163S. PubMed ID: 1818150
[TBL] [Abstract][Full Text] [Related]
2. In vitro activities of lytic peptides against the sporozoites of Cryptosporidium parvum.
Arrowood MJ; Jaynes JM; Healey MC
Antimicrob Agents Chemother; 1991 Feb; 35(2):224-7. PubMed ID: 1708975
[TBL] [Abstract][Full Text] [Related]
3. [Highly Active AntiRetroviral Therapy and cryptosporidiosis].
Morales Gomez MA
Parassitologia; 2004 Jun; 46(1-2):95-9. PubMed ID: 15305695
[TBL] [Abstract][Full Text] [Related]
4. Phospholipases and cationic peptides inhibit Cryptosporidium parvum sporozoite infectivity by parasiticidal and non-parasiticidal mechanisms.
Carryn S; Schaefer DA; Imboden M; Homan EJ; Bremel RD; Riggs MW
J Parasitol; 2012 Feb; 98(1):199-204. PubMed ID: 21787211
[TBL] [Abstract][Full Text] [Related]
5. Protective monoclonal antibody defines a circumsporozoite-like glycoprotein exoantigen of Cryptosporidium parvum sporozoites and merozoites.
Riggs MW; Stone AL; Yount PA; Langer RC; Arrowood MJ; Bentley DL
J Immunol; 1997 Feb; 158(4):1787-95. PubMed ID: 9029117
[TBL] [Abstract][Full Text] [Related]
6. Cryptosporidium parvum: identification of a new surface adhesion protein on sporozoite and oocyst by screening of a phage-display cDNA library.
Yao L; Yin J; Zhang X; Liu Q; Li J; Chen L; Zhao Y; Gong P; Liu C
Exp Parasitol; 2007 Apr; 115(4):333-8. PubMed ID: 17097085
[TBL] [Abstract][Full Text] [Related]
7. Improved efficacy of dinitroaniline analogs for use as anti-cryptosporidial drugs.
Mead JR; Benbow JW; Garmon D; Stewart J
J Eukaryot Microbiol; 1999; 46(5):62S-63S. PubMed ID: 10519250
[No Abstract] [Full Text] [Related]
8. Treatment with agmatine inhibits Cryptosporidium parvum infection in infant mice.
Moore D; Waters WR; Wannemuehler MJ; Harp JA
J Parasitol; 2001 Feb; 87(1):211-3. PubMed ID: 11227893
[TBL] [Abstract][Full Text] [Related]
9. Unexpected activity of beta-cyclodextrin against experimental infection by Cryptosporidium parvum.
Castro-Hermida JA; Freire-Santos F; Oteiza-Löpez AM; Ares-Mazás E
J Parasitol; 2000 Oct; 86(5):1118-20. PubMed ID: 11128490
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory activities of epidermal growth factor receptor tyrosine kinase-targeted dihydroxyisoflavone and trihydroxydeoxybenzoin derivatives on Sarcocystis neurona, Neospora caninum, and Cryptosporidium parvum development.
Gargala G; Baishanbo A; Favennec L; François A; Ballet JJ; Rossignol JF
Antimicrob Agents Chemother; 2005 Nov; 49(11):4628-34. PubMed ID: 16251305
[TBL] [Abstract][Full Text] [Related]
11. The immunological selection of recombinant peptides from Cryptosporidium parvum reveals 14 proteins expressed at the sporozoite stage, 7 of which are conserved in other apicomplexa.
Trasarti E; Pizzi E; Pozio E; Tosini F
Mol Biochem Parasitol; 2007 Apr; 152(2):159-69. PubMed ID: 17267054
[TBL] [Abstract][Full Text] [Related]
12. Evidence for mitochondrial-derived alternative oxidase in the apicomplexan parasite Cryptosporidium parvum: a potential anti-microbial agent target.
Roberts CW; Roberts F; Henriquez FL; Akiyoshi D; Samuel BU; Richards TA; Milhous W; Kyle D; McIntosh L; Hill GC; Chaudhuri M; Tzipori S; McLeod R
Int J Parasitol; 2004 Mar; 34(3):297-308. PubMed ID: 15003491
[TBL] [Abstract][Full Text] [Related]
13. IL-12 protects immunocompetent and immunodeficient neonatal mice against infection with Cryptosporidium parvum.
Urban JF; Fayer R; Chen SJ; Gause WC; Gately MK; Finkelman FD
J Immunol; 1996 Jan; 156(1):263-8. PubMed ID: 8598471
[TBL] [Abstract][Full Text] [Related]
14. Bobel-24 activity against Cryptosporidium parvum in cell culture and in a SCID mouse model.
Rueda C; Fenoy S; Simón F; Del Aguila C
Antimicrob Agents Chemother; 2008 Mar; 52(3):1150-2. PubMed ID: 18160525
[TBL] [Abstract][Full Text] [Related]
15. New potential therapies for cryptosporidiosis: an analysis of variables affecting drug efficacy.
Rehg J
Folia Parasitol (Praha); 1994; 41(1):23-6. PubMed ID: 8050751
[TBL] [Abstract][Full Text] [Related]
16. In vitro assays of maduramicin activity against Cryptosporidium parvum.
Arrowood MJ; Xie LT; Hurd MR
J Eukaryot Microbiol; 1994; 41(5):23S. PubMed ID: 7804225
[No Abstract] [Full Text] [Related]
17. Inhibition of cryptosporidium parvum in vitro by 9-(alkylthio)acridine derivatives.
Khalifa L; Rosales MJ; Mascaro C; Karolak-Wojciechowska J; Bsiri N; Brouant P; Barbe J
Arzneimittelforschung; 2000 Feb; 50(2):163-6. PubMed ID: 10719621
[TBL] [Abstract][Full Text] [Related]
18. An immunosuppressed rat model for evaluation of anti-Cryptosporidium activity of sinefungin.
Brasseur P; Favennec L; Leméteil D; Roussel F; Ballet JJ
Folia Parasitol (Praha); 1994; 41(1):13-6. PubMed ID: 8050749
[TBL] [Abstract][Full Text] [Related]
19. Effect of egg yolk antibody on experimental Cryptosporidium parvum infection in scid mice.
Kobayashi C; Yokoyama H; Nguyen SV; Kodama Y; Kimata T; Izeki M
Vaccine; 2004 Nov; 23(2):232-5. PubMed ID: 15531042
[TBL] [Abstract][Full Text] [Related]
20. Activity of benzimidazoles against cryptosporidiosis in neonatal BALB/c mice.
Fayer R; Fetterer R
J Parasitol; 1995 Oct; 81(5):794-5. PubMed ID: 7472880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
